Opinion

Video

SPOTLIGHT Trial and 18F-rhPSMA-7.3 for Prostate Cancer

Author(s):

Brian Helfand, MD, PhD,Brian Chapin, MD

Experts in prostate cancer evaluate the data from the SPOTLIGHT trial and the use of 18F-rhPSMA-7.3 for prostate cancer.

Current Time 0:00
Duration 8:26
Loaded: 1.95%
Stream Type LIVE
Remaining Time 8:26
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
    • en (Main), selected

    Newsletter

    Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

    Subscribe Now!
    Related Videos
    2 experts in this video
    Fitting Oral ADT Options Into the Prostate Cancer Treatment Plans
    2 experts in this video
    The Current Landscape of ADT in Prostate Cancer
    Christine Ibilibor, MD, highlights study of racial differences in abiraterone use
    Christine Ibilibor, MD, highlights study of racial differences in abiraterone use
    Laura Davis, MD, on persistent poverty and early onset prostate cancer
    Laura Davis, MD, on persistent poverty and early onset prostate cancer
    Alicia Morgans, MD, highlights the phase 3 ARASTEP trial
    Alicia Morgans, MD, highlights the phase 3 ARASTEP trial
    Ruben Olivares, MD, answers a question during a Zoom video interview
    Ruben Olivares, MD, discusses HIFU and remote prostate cancer care
    Mitchell Huang, MD, on the cost-effectiveness of transperineal vs transrectal prostate biopsy
    Mitchell Huang, MD, on the cost-effectiveness of transperineal vs transrectal prostate biopsy
    Alicia Morgans, MD, on QOL outcomes with darolutamide plus ADT in mHSPC
    Alicia Morgans, MD, on QOL outcomes with darolutamide plus ADT in mHSPC
    Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
    Post-RP incontinence: Low procedure rates examined
    Bashir Al Hussein Al Awamlh, MD, MPH, answers a question during a Zoom video interview
    Data link incontinence severity to post-radical prostatectomy care
    Related Content
    Aquablation procedures for prostate cancer completed at ambulatory surgery center
    July 24th 2025

    Aquablation procedures for prostate cancer completed at ambulatory surgery center

    Hannah Clarke
    The WATER IV PCa trial is comparing first-line Aquablation therapy with radical prostatectomy for the treatment of patients with localized prostate cancer.
    Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025 | Credit: Urology Times
    April 27th 2025

    Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025

    Amy M. Pearlman, MD Helen L. Bernie, DO, MPH
    Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.
    Irreversible electroporation with NanoKnife found safe, effective for prostate tissue ablation
    Published: July 22nd 2025 | Updated: July 23rd 2025

    Irreversible electroporation with NanoKnife found safe, effective for prostate tissue ablation

    Hannah Clarke
    The PRESERVE trial met its primary end point by demonstrating a negative in-field biopsy rate of 71% at 12 months.
    Dr. Murphy on increasing diversity in cancer clinical trials
    February 29th 2024

    Dr. Murphy on increasing diversity in cancer clinical trials

    Urology Times staff
    In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
    Prostate cancer cells dividing | Image Credit: © PRB ARTS - stock.adobe.com
    July 18th 2025

    Phase 3 TALAPRO-2 data of talazoparib plus enzalutamide published in The Lancet

    Hannah Clarke
    In both cohorts, the combination of talazoparib plus enzalutamide led to a significant improvement in overall survival vs enzalutamide alone.
    Urology in focus: Key moments from 2025
    July 18th 2025

    Urology in focus: Key moments from 2025

    Hannah Clarke
    Take a look back through some of the top stories from the first half of the year.
    © 2025 MJH Life Sciences

    All rights reserved.